GSK signed a 12-asset licensing deal with Hengrui Pharma. Generic erosion on Vyvanse continued to hurt Takeda. Celltrion is ...

Britain's GSK and China's Jiangsu Hengrui Pharmaceuticals have agreed on a $500 million deal to develop up to a dozen new ...

China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

The deal, which focuses first on a COPD drug GSK believes holds “best-in-class” potential, could involve a dozen medicines ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

The deal would give GSK the rights to develop the drug for HRS-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

GSK and Hengrui Pharma signed a global deal for up to 12 drugs, including COPD therapy, with milestone payments totaling $12 ...

GSK is paying $500M upfront for rights to a series of Hengrui drugs, the latest case of a pharma company looking to a Chinese ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

Asian equities were mostly higher overnight as Vietnam and Indonesia outperformed while Japan and India underperformed. Hong ...